foxo4-dri senolytic peptide human trial 2024
foxo4-dri senolytic peptide human trial 2024 regulates endothelial cell senescence via the P53 signaling pathway Senolytics: from pharmacological inhibitors to
Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging
USD29.94
USD66.94
Pay in 4 interest-free payments of $7.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
